Terns Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -108 | |||
EBITDA | -24,577 | -23,921 | -27,258 | -25,735 |
EBIT | -24,589 | -24,029 | -27,427 | -25,949 |
Net Income | -24,635 | -24,093 | -23,908 | -21,799 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -19,773 | -18,880 | -24,446 | -14,584 |
Cash | 150,698 | 145,966 | 139,023 | 161,439 |
Basic Shares | 91,701 | 91,575 | 91,473 | 91,240 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1,000 |
Gross Profit | -881 | -1,032 | 1,000 | |
EBITDA | -100,975 | -101,677 | -60,997 | -49,348 |
EBIT | -101,871 | -102,558 | -62,029 | -49,860 |
Net Income | -88,853 | -90,210 | -60,345 | -50,158 |
Net Change In Cash | 0 | 0 | 0 | 1,000 |
Cost of Revenue | 95,714 | |||
Free Cash Flow | -70,058 | -67,442 | -49,384 | -42,167 |
Cash | 161,439 | 79,926 | 143,235 | 47,699 |
Basic Shares | 79,507 | 71,259 | 36,033 | 25,269 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.27 |
2025-06-30 | -$0.26 |
2025-03-31 | -$0.26 |
